<DOC>
	<DOC>NCT02109562</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia.</brief_summary>
	<brief_title>Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients</brief_title>
	<detailed_description>This will be a double-blind, placebo-controlled, Phase III study with 90 mg and 120 mg doses of RBP-7000 compared with placebo over an 8-week treatment period.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Males and females between the ages of 18 to 55 years, inclusive Diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual, Edition 4, text revision (DSMIVTR) criteria Subjects who are deemed "valid" by the State, Assessability, Face, Ecological, and Rule (SAFER) interview Subjects who are otherwise healthy on the basis of their physical examination Subjects who have an improvement in their total Positive and Negative Syndrome Scale (PANSS) score of 20% or greater between the initial screening visit and the first day of treatment. Subjects taking daily oral risperidone at a dose â‰¥ 6 mg/day Subjects who have received a depot antipsychotic within 120 days of screen Subjects with treatment resistant schizophrenia, as judged by the investigator, who have been treated with antipsychotics for adequate durations and with adequate dosages.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic</keyword>
	<keyword>Schizophrenias</keyword>
	<keyword>Risperidone</keyword>
</DOC>